Who Paid My Doc
Marc Musson
Physical Medicine & Rehabilitation Corvallis, OR Doctor of Osteopathy
NPI 1649589896 CMS profile 808807
2358 Nw Kings Blvd, Corvallis, OR 97330
General payments
$824
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Marc Musson of Corvallis, OR is reported in the CMS Open Payments database as having received $824 across 25 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $590 | 18 | |
| 2024 | General | $220 | 6 | |
| 2019 | General | $15 | 1 |
Beside peers
- Marc Musson
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Marc Musson were reported at $590. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Marc Musson | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15 | $133 | $45–$390 | $163 |
| 2020 | $0 | $88 | $29–$272 | $114 |
| 2021 | $0 | $116 | $33–$360 | $132 |
| 2022 | $0 | $123 | $40–$378 | $149 |
| 2023 | $0 | $131 | $43–$396 | $160 |
| 2024 | $220 | $141 | $45–$409 | $164 |
| 2025 | $590 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,203
Drug cost
$21,979
Branded share of claims
38%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 265 | $5,940 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 146 | $3,712 | |
| Oxycodone Hcl | Generic | 189 | $3,581 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 27 | $1,738 | |
| Gabapentin | Generic | 67 | $1,381 | |
| Buprenorphine Hcl | Generic | 21 | $825 | |
| Tramadol Hcl | Generic | 68 | $643 | |
| Celecoxib | Generic | 34 | $629 | |
| Hydromorphone Hcl | Generic | 30 | $597 | |
| Cyclobenzaprine Hcl | Generic | 52 | $544 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$269,068
Medicare patients
486
Services billed
5,427
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 68% | |
| Depression | 29% | |
| Diabetes | 26% | |
| Ischemic heart disease | 18% | |
| Chronic kidney disease | 16% | |
| Atrial fibrillation | 12% | |
| COPD | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 202 | 1,335 | $1,001 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 210 | 1,129 | $116 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 53 | 761 | $68 |
| Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 | Office | 28 | 31 | $0 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
25 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Physical Medicine & Rehabilitation in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.